Arpeggio Bio is a biotechnology company that develops novel therapies for cancer and other diseases. The company's proprietary platform is based on a new class of small molecules that selectively target cancer cells while sparing healthy cells. Arpeggio Bio's lead product candidate is currently in preclinical development for the treatment of solid tumors. The company was founded in 2018 and is headquartered in San Francisco, California.